Literature DB >> 23186165

Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells.

Virna Marin1, Elisabetta Cribioli, Brian Philip, Sarah Tettamanti, Irene Pizzitola, Andrea Biondi, Ettore Biagi, Martin Pule.   

Abstract

Use of adoptive T-cell therapy (ACT) is increasing; however, T-cell therapy can result in severe toxicity. Consequently, several suicide-gene strategies that allow selective destruction of the infused T cells have been described. We compared effectiveness of four such strategies in vitro in Epstein Barr virus (EBV)-cytotoxic T lymphocytes (CTLs). Herpes simplex virus thymidine kinase (HSV-TK), human inducible caspase 9 (iCasp9), mutant human thymidylate kinase (mTMPK), and human CD20 codon optimized genes were cloned in frame with 2A-truncated codon optimized CD34 (dCD34) in a retroviral vector. Codon-optimization considerably improved CD20 expression. EBV-CTLs could be efficiently transduced in all constructs, with transgene expression similar to the control vector containing dCD34 alone. Expression was maintained for prolonged cultures. Expression of the suicide genes was not associated with alterations in immunophenotype, proliferation, or function of CTLs. Activation of HSV-TK, iCasp9, and CD20 ultimately resulted in equally effective destruction of transduced T cells. However, while iCasp9 and CD20 effected immediate cell-death induction, HSV-TK-expressing T cells required 3 days of exposure to ganciclovir to reach full effect. mTMPK-transduced cells showed lower T-cell killing all time points. Our results suggest that the faster activity of iCasp9 might be advantageous in treating certain types of acutely life-threatening toxicity. Codon-optimized CD20 has potential as a suicide gene.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23186165      PMCID: PMC4015080          DOI: 10.1089/hgtb.2012.050

Source DB:  PubMed          Journal:  Hum Gene Ther Methods        ISSN: 1946-6536            Impact factor:   2.396


  34 in total

1.  Safer CARS.

Authors:  Helen E Heslop
Journal:  Mol Ther       Date:  2010-04       Impact factor: 11.454

2.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

Review 3.  Rituximab: mechanism of action.

Authors:  George J Weiner
Journal:  Semin Hematol       Date:  2010-04       Impact factor: 3.851

4.  Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.

Authors:  Renier Brentjens; Raymond Yeh; Yvette Bernal; Isabelle Riviere; Michel Sadelain
Journal:  Mol Ther       Date:  2010-04       Impact factor: 11.454

5.  Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.

Authors:  Chrystal U Louis; Barbara Savoldo; Gianpietro Dotti; Martin Pule; Eric Yvon; G Doug Myers; Claudia Rossig; Heidi V Russell; Oumar Diouf; Enli Liu; Hao Liu; Meng-Fen Wu; Adrian P Gee; Zhuyong Mei; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner
Journal:  Blood       Date:  2011-10-07       Impact factor: 22.113

Review 6.  Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.

Authors:  Steven A Rosenberg
Journal:  Nat Rev Clin Oncol       Date:  2011-08-02       Impact factor: 66.675

7.  Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies.

Authors:  M Introna; A M Barbui; F Bambacioni; C Casati; G Gaipa; G Borleri; S Bernasconi; T Barbui; J Golay; A Biondi; A Rambaldi
Journal:  Hum Gene Ther       Date:  2000-03-01       Impact factor: 5.695

8.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Authors:  Renier J Brentjens; Isabelle Rivière; Jae H Park; Marco L Davila; Xiuyan Wang; Jolanta Stefanski; Clare Taylor; Raymond Yeh; Shirley Bartido; Oriana Borquez-Ojeda; Malgorzata Olszewska; Yvette Bernal; Hollie Pegram; Mark Przybylowski; Daniel Hollyman; Yelena Usachenko; Domenick Pirraglia; James Hosey; Elmer Santos; Elizabeth Halton; Peter Maslak; David Scheinberg; Joseph Jurcic; Mark Heaney; Glenn Heller; Mark Frattini; Michel Sadelain
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

9.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.

Authors:  Martin A Pule; Barbara Savoldo; G Doug Myers; Claudia Rossig; Heidi V Russell; Gianpietro Dotti; M Helen Huls; Enli Liu; Adrian P Gee; Zhuyong Mei; Eric Yvon; Heidi L Weiss; Hao Liu; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner
Journal:  Nat Med       Date:  2008-11-02       Impact factor: 53.440

10.  Inducible apoptosis as a safety switch for adoptive cell therapy.

Authors:  Antonio Di Stasi; Siok-Keen Tey; Gianpietro Dotti; Yuriko Fujita; Alana Kennedy-Nasser; Caridad Martinez; Karin Straathof; Enli Liu; April G Durett; Bambi Grilley; Hao Liu; Conrad R Cruz; Barbara Savoldo; Adrian P Gee; John Schindler; Robert A Krance; Helen E Heslop; David M Spencer; Cliona M Rooney; Malcolm K Brenner
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

View more
  59 in total

1.  Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: an in vitro proof-of-concept.

Authors:  C Leboeuf; J Roser-Schilder; M Lambotin; S Durand; T Wu; C Fauvelle; B Su; E Bôle-Richard; M Deschamps; C Ferrand; P Tiberghien; P Pessaux; T F Baumert; E Robinet
Journal:  Gene Ther       Date:  2014-11-13       Impact factor: 5.250

2.  T cell avidity and tumor immunity: problems and solutions.

Authors:  Arthur A Hurwitz; Steven M Cuss; Katherine E Stagliano; Ziqiang Zhu
Journal:  Cancer Microenviron       Date:  2013-12-20

3.  EBV-related lymphomas: new approaches to treatment.

Authors:  Jennifer A Kanakry; Richard F Ambinder
Journal:  Curr Treat Options Oncol       Date:  2013-06

4.  Image-guided intrathymic injection of multipotent stem cells supports lifelong T-cell immunity and facilitates targeted immunotherapy.

Authors:  Andrea Z Tuckett; Raymond H Thornton; Yusuke Shono; Odette M Smith; Emily R Levy; Fabiana M Kreines; Marcel R M van den Brink; Johannes L Zakrzewski
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

Review 5.  Immunotherapy for opportunistic infections: Current status and future perspectives.

Authors:  Shigeo Fuji; Jürgen Löffler; Hermann Einsele; Markus Kapp
Journal:  Virulence       Date:  2016-07-06       Impact factor: 5.882

6.  In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells.

Authors:  Céline Leboeuf; Laurent Mailly; Tao Wu; Gaetan Bour; Sarah Durand; Nicolas Brignon; Christophe Ferrand; Christophe Borg; Pierre Tiberghien; Robert Thimme; Patrick Pessaux; Jacques Marescaux; Thomas F Baumert; Eric Robinet
Journal:  Mol Ther       Date:  2013-12-06       Impact factor: 11.454

Review 7.  Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.

Authors:  Alisa C Dong; Stefano Rivella
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 8.  Improving the safety of T-Cell therapies using an inducible caspase-9 gene.

Authors:  Xiaoou Zhou; Malcolm K Brenner
Journal:  Exp Hematol       Date:  2016-07-26       Impact factor: 3.084

9.  Conditional control of suicide gene expression in tumor cells with theophylline-responsive ribozyme.

Authors:  Y Zhang; J Wang; H Cheng; Y Sun; M Liu; Z Wu; R Pei
Journal:  Gene Ther       Date:  2016-11-22       Impact factor: 5.250

Review 10.  Engineered T cells for cancer treatment.

Authors:  Usanarat Anurathapan; Ann M Leen; Malcolm K Brenner; Juan F Vera
Journal:  Cytotherapy       Date:  2013-11-13       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.